The Standard & Poor�� 500 Index (SPX) rose, heading for its biggest monthly gain since January, as investors analyzed corporate earnings and awaited results from the Federal Reserve�� two-day meeting.
Eastman Chemical Co. and Goodyear Tire & Rubber Co. jumped more than 6.3 percent as earnings topped estimates. Mosaic Co. and Agrium Inc. plunged at least 5.4 percent after OAO Uralkali ended limits on potash production and said the price of the soil nutrient may fall 25 percent. Coach Inc. lost 7.9 percent as discounts and weak handbag sales hurt revenue in North America.
The S&P 500 added less than 0.1 percent to 1,685.96 at 4 p.m. in New York, after swinging between gains and losses during the trading session. The Dow Jones Industrial Average fell 1.38 points to 15,520.59 today. About 5.9 billion shares changed hands, 7.7 percent below the three-month average.
��e��e waiting again to hear what the Fed has to say because everybody�� on tenterhooks,��Sarah Hunt, an associate fund manager and analyst who helps oversee $4.5 billion at Purchase, New York-based Alpine Woods Capital Investors LLC, said in a phone interview. ��arnings have been a mixed bag but I would say mostly positive.��
10 Best Regional Bank Stocks To Invest In 2015: Cambridge Heart Inc (CAMH)
Cambridge Heart, Inc., incorporated on January 16, 1990, is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. The Company's products incorporate its technology for the measurement of Microvolt T-Wave Alternans (MTWA). The MTWA Test is conducted by elevating the patient's heart rate through exercise as performed on a treadmill similar to a stress test, pharmacologic agents, or pacing with electrical pulses.
The Company's products, including its first generation HearTwave System and second generation HearTwave II System, CH 2000 Cardiac Stress Test System, MTWA original equipment manufacturer (OEM) Module (MTWA Module) and Micro-V Alternans Sensors have received 510(k) clearance from the United States Food and Drug Administration (FDA) for sale in the United States. The Company's products have also received the Conformite Europeenne (CE) mark for sale in Europe. The Company's first generation HearTwave System, CH 2000 Cardiac Stress Test System and the HearTwave II System have been approved for sale by the Japanese Ministry of Health Labor and Welfare.
The Company's 510(k) clearance allows the Company's MTWA Test to be used to test patients with known, suspected, or at risk of ventricular tachyarrhythmia and/or sudden cardiac arrest, and allows the claim that its MTWA Test is predictive of those events. The MTWA Module is designed to work with existing cardiac stress test platforms distributed by other manufacturers as an add-on module to enable MTWA testing to be performed using the Company's Micro-V Alternans Sensors.
The Company's HearTwave II System, which has replaced the Company's original HearTwave System, is used to perform both MTWA testing and standard cardiac stress testing. In addition to MTWA measurement, the Company's HearTwave II System is a cardiac diagnostic system designed to support a range of customized protocols for the conduct of cardiac exercise stress testing. The Comp! any's Micro-V Alternans Sensors are single patient use, multi-segment electrodes. The Company's CH2000 is a cardiac diagnostic system designed to support a range of customized protocols for the conduct and measurement of cardiac exercise stress testing.
The Company competes with GE Medical Systems.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap stocks Cambridge Heart, Inc (OTCMKTS: CAMH), Abby Inc (OTCMKTS: ABBY) and Grillit Inc (OTCMKTS: GRLT) surged 176.92%, 71.2% and 24.07%, respectively. Of course, that was last week and today is a new trading week. So what should investors and traders alike be prepared for this week with these three small caps? Here is a closer look to help you decide on an investing or trading strategy:
Cambridge Heart, Inc (OTCMKTS: CAMH) Recently Changed Its BoardSmall cap Cambridge Heart, Inc is a healthcare company engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. On Friday, Cambridge Heart, Inc surged 176.92% to $0.018 for a market cap of $1.80 million plus CAMH is up 20% since the start of the year and down 86.1% over the past five years according to Google Finance.
10 Best Forestry Stocks To Buy Right Now: Limoneira Co(LMNR)
Limoneira Company engages in agribusiness and real estate development businesses primarily in the United States. The Company operates in three reportable operating segments; Agribusiness, Rental Operations, and Real Estate Development. The agribusiness segment farms, packages, and sells lemons directly to food service, wholesale, and retail customers. It also grows oranges, and a range of specialty citrus and other crops, such as pummelos, Moro blood oranges, Cara Cara oranges, Satsuma mandarin oranges, Minneola tangelos, pistachios, cherries, and Star Ruby grapefruits. This segment has approximately 1,766 acres of lemons; 1,254 acres of avocados; 1,062 acres of oranges; and 401 acres of specialty citrus and other crops Ventura and Tulare Counties, California. The Rental Operations segment rents residential and commercial facilities; leases land; and provides organic recycling services. This segment owns and maintains approximately 188 residential housing units located in Ventura and Tulare Counties; owns various commercial office buildings and a multi-use facility consisting of a retail convenience store, gas station, car wash, and quick-serve restaurant; and leases approximately 586 acres of land to third party agricultural tenants. The Real Estate Development segment develops land parcels, multi-family housing, and single-family homes. This segment has 1,873 units in various stages of planning and development. The company also processes and packs lemons lemons grown by third parties. Limoneira Company was founded in 1893 and is headquartered in Santa Paula, California.
Advisors' Opinion:- [By Eric Volkman]
Limoneira (NASDAQ: LMNR ) is maintaining its dividend. The company this week declared a distribution of $0.03750 per share, to be handed out July 16 to shareholders of record as of July 8.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Limoneira (Nasdaq: LMNR ) , whose recent revenue and earnings are plotted below. - [By John Udovich]
Last Friday, small cap Farmland Partners Inc (NYSEMKT: FPI) had an IPO to join Gladstone Land Corp (NASDAQ: LAND), Alico, Inc (NASDAQ: ALCO) and Limoneira Company (NASDAQ: LMNR) as the latest option for retail investors seeking a way to invest in American farmland. After all, there is that old quote attributed to Mark Twain: "Buy land, they're not making it anymore." Moreover, February Wall Street Journal article noted that From 2009 to mid-2013, average prices for agricultural land in the�US rose by half while in Iowa, Nebraska and some other Midwest farm states, prices more than doubled. However, the same article noted that there is mounting evidence that the farmland�boom is fizzling out as�farmland prices in Iowa fell 3% over the second half of last year and those in Nebraska fell 1%. The good news though is that today's agricultural sector looks markedly different than it did during the last farmland bust back in�the early 1980s while Greyson Colvin, the managing partner at investment manager Colvin & Co. (which owns about 7,000 acres of farmland), was quoted as saying: "We think this next 12 months is going to be the best window we've had in the past five years [to invest in farmland].��/p>
10 Best Forestry Stocks To Buy Right Now: Symantec Corporation(SYMC)
Symantec Corporation provides security, storage, and systems management solutions internationally. The company?s Consumer segment delivers Internet security, PC tune-up, and online backup solutions and services to individual users and home offices. Its Security and Compliance segment provides solutions for endpoint security and management, compliance, messaging management, data loss prevention, encryption, and authentication services to large, medium, and small-sized businesses, as well as offers solutions through its software-as-a-service (SaaS) security offerings. This segment?s products enable customers to secure, provision, and remotely manage their laptops, PCs, mobile devices, and servers. The company?s Storage and Server Management segment provides storage and server management, backup, archiving, and data protection solutions across heterogeneous storage and server platforms, as well as solutions delivered through its SaaS offerings to large, medium, and small-s ized businesses. Symantec?s Services segment offers implementation services and solutions, including consulting, business critical services, education, and managed security services. The company also provides various enterprise support offerings, such as annual maintenance support contracts, including content, upgrades, and technical support. It sells its products through its eCommerce platform, as well as through distributors, direct marketers, Internet-based resellers, system builders, ISPs, and retail locations worldwide. Symantec markets and sells its products through distributors, retailers, direct marketers, Internet-based resellers, original equipment manufacturers, system builders, and Internet service providers; and its e-commerce channels, as well as direct sales force, value-added and large account resellers, and system integrators. The company was founded in 1982 and is headquartered in Mountain View, California.
Advisors' Opinion:- [By Reuters]
Peter Parks, AFP/Getty ImagesThe 12-story building in Shanghai's northern suburb of Gaoqiao where a Chinese military-led hacking group allegedly conducted a series of attacks on U.S. companies networks. BOSTON -- Cybersecurity company FireEye has acquired Mandiant, the computer forensics specialist best known for unveiling a secretive Chinese military unit believed to be behind a series of hacking attacks on U.S. companies. FirEye (FEYE) shares jumped more than 20 percent after Thursday's announcement of the $1.05 billion cash-and-stock deal, which FireEye said closed Monday. It unites two companies with relatively new technologies for thwarting cyber attacks, and brings together two of the most-respected executives in the security industry: FireEye CEO Dave DeWalt and Mandiant founder Kevin Mandia. While sales of older anti-virus products have been on the decline, security experts expect strong growth in both FireEye's cloud-based systems for detecting malicious software and Mandiant's software that analyzes cyber attacks. About a year ago the two companies entered into a technology development agreement that made it easier to deploy their products together. With the merger, FireEye will gain Mandiant's team of forensics investigators. "They have these very strong Navy 'cyber' Seals who respond to breaches and are very good at what they do," DeWalt said about Mandiant. He had previously served as chairman of Mandiant's board. "My aim is to create the strongest security company in the world," DeWalt said in an interview. FireEye, which has yet to post a profit, said the acquisition will be immediately accretive to earnings and expects the combined company's revenue to grow about 50 percent this year. In comparison, Symantec (SYMC), the biggest maker of anti-virus software, has said it expects fiscal 2014 revenue to drop 3 percent to 4 percent. Mandiant is best known for its forensics services. The company rose to prominence in February 2013 when it pu
- [By Shauna O'Brien]
On Thursday, Morgan Stanley reported that it has downgraded security and storage management company Symantec Corporation (SYMC).
Morgan Stanley has cut its rating on SYMC to an “Equal Weight.” Analysts believe that the company lacks near term catalysts.
Symantec shares were down 55 cents, or 2.18%, during pre-market trading Thursday. The stock is up 34% YTD.
10 Best Forestry Stocks To Buy Right Now: Lazard LTD. (LAZ)
Lazard Ltd., together with its subsidiaries, operates as a financial advisory and asset management firm. The company�s Financial Advisory segment offers various advisory services on mergers and acquisitions, and other strategic matters, as well as on restructurings, capital structure, capital raising, and other financial matters. Its Asset Management segment provides investment solutions and investment management services in equity and fixed income strategies; and alternative investments and private equity funds. The company serves corporations, governments, institutions, partnerships, and individual clients. It operates from 42 cities across 27 countries in Europe, North America, Asia, Australia, the Middle East, and Central and South Americas. Lazard Ltd. was founded in 1848 and is based in Hamilton, Bermuda.
Advisors' Opinion:- [By Marc Bastow]
Financial advisory and asset manager Lazard (LAZ) raised its quarterly dividend 20% to 30 cents per share, payable on Feb. 21 to shareholders of record as of Feb. 10.
LAZ Dividend Yield: 2.79% - [By Robert Wall]
Bookrunners for the sale are Goldman Sachs Group Inc., UBS AG (UBSN), Barclays Plc (BARC) and Merrill Lynch & Co., with Investec Ltd., Nomura Bank International Plc and RBC Europe Ltd. lead managers, said the government, which is being advised by Lazard Ltd. (LAZ)
- [By EXPstocktrader]
1) Lazard (LAZ): Management meetings highlight under-appreciated earnings drivers; raising PT to $85; BUY
2) Bank of America/Merrill Lynch (BAC): Questcor Pharmaceuticals is upgraded from "neutral" to "buy." The target price has been raised from $58 to $80.
- [By Ben Levisohn]
Horowitz predicts Lazard (LAZ), which returned 55% last year, to gain just 4% in 2014 as weaker merger & acquisition activity will weight on earnings.
10 Best Forestry Stocks To Buy Right Now: Intercept Pharmaceuticals Inc (ICPT)
Intercept Pharmaceuticals, Inc., incorporated on September 4, 2002, is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�� product candidates treat orphan and more prevalent liver diseases for which there are limited therapeutic solutions. The Company�� product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.
The Company�� clinical focus is on the development of OCA, orally administered, first-in-class FXR agonist that has broad liver-protective properties and may a variety of chronic insults to the liver that cause fibrosis, which can eventually lead to cirrhosis, liver transplant and death. The Company owns worldwide rights to OCA outside of Japan and China, where it has licensed the compound to Dainippon Sumitomo Pharma, or DSP, and granted it an option to license OCA in certain other Asian countries.The Company is sponsoring an independent study involving more than ten leading PBC centers in North America and Europe, or collectively the Global PBC Study Group, that are pooling their long-term patient data to evaluate the relationship between biochemical and clinical endpoints.
The Company competes with Eli Lilly, Exelixis, Inc., Phenex Pharmaceuticals AG, , Johnson & Johnson, NovImmune SA, Dr. Falk Pharma GmbH, Galmed Medical Researc! h Ltd., Immuron Ltd., Mochida Pharmaceutical Co., Ltd., NasVax Ltd. , Raptor Pharmaceutical Corp. Astellas Pharma US, Inc., AstraZeneca, Salix Pharmaceuticals, Inc. and Tioga Pharmaceuticals, Inc.
Advisors' Opinion:- [By John Udovich]
It�� a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or�pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for�Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ:�RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:
- [By Sue Chang and Ben Eisen]
Shares of Intercept Pharmaceuticals Inc. (ICPT) �soared another 62% following a surge of 281% on Thursday. The company announced on Thursday that halted the trial of its obeticholic acid drug to treat nonalcoholic steatohepatitis (NASH) ahead of schedule on positive results. The drug could be the first reliable treatment option for patients facing liver transparent and as a result, obeticholic acid could be a true blockbuster, according to Jim Molloy, an analyst at Janney Capital Markets.
10 Best Forestry Stocks To Buy Right Now: Lennar Corp.(LEN)
The third largest U.S. homebuilder by revenue reported exceptional Q3 results, as its earnings more than quadrupled, primarily as a result of an increase in new-home demand. The reported net income of 40c was well ahead of last year's 11c, and the forecasted 28c.
According to the company's CEO, Stuart Miller, "The homebuilding business is beginning to revert to normal, and that's a positive for the U.S. economy in general, which is in turn good for sustained recovery in the housing market. Overall demand has been improving and we've seen a consistent sales pace at improving prices."
LEN's contract backlog, which is an indicator of future sales, rose by a whopping 79% on a YoY basis. Its average selling price of delivered homes also increased to $258,000 from last year's $247,000.
Advisors' Opinion:- [By Eileen Rojas]
Lennar reports demand in its markets outpacing supply
Lennar's (NYSE: LEN ) second-quarter net earnings for the period ended May 31 were $137.4 million, or $0.61 per diluted share. Earnings were hurt by the partial reversal of a deferred tax asset worth $41.3 million, or $0.18 per diluted share. Note that a deferred tax asset is used to decrease the company's tax expense in future periods.�Earnings for the second quarter dropped about 70% from $452.7 million, or $2.06 per diluted shares in the previous year�.� - [By Jake L'Ecuyer]
Top Headline
Lennar (NYSE: LEN) reported better-than-expected first-quarter earnings. Lennar's quarterly earnings surged to $78.1 million, or $0.35 per share, versus $57.5 million, or $0.26 per share, in the year-earlier quarter. Its revenue rose 38% to $1.4 billion. However, analysts were estimating earnings of $0.28 per share on revenue of $1.25 billion. - [By John Maxfield]
We're also starting to see the proceeds of the nascent recovery reflected in the earnings of homebuilders. Last week, Lennar (NYSE: LEN ) and KB Home� (NYSE: KBH ) , two of the nation's largest homebuilders, reported markedly improved results. Lennar's home deliveries shot up by 36% on a year-over-year basis while KB Home's increased by 39%. And in PulteGroup's (NYSE: PHM ) first-quarter earnings release in April, its chief executive officer observed that homebuyers are "feeling a greater sense of urgency given the combination of limited product inventory and rising prices found in many markets throughout the country."
10 Best Forestry Stocks To Buy Right Now: Hawaiian Holdings Inc.(HA)
Hawaiian Holdings, Inc., through its subsidiary, Hawaiian Airlines, Inc., engages in the scheduled air transportation of passengers and cargo. It offers daily service on transpacific routes between Hawaii and Los Angeles, Oakland, Sacramento, San Diego, San Francisco, and San Jose, California; Las Vegas, Nevada; Phoenix, Arizona; Portland, Oregon; and Seattle, Washington, as well as daily service on its inter island routes among the four islands of the State of Hawaii. The company also provides scheduled service on its Pacific routes between Hawaii and Pago Pago, American Samoa; Papeete, Tahiti; Sydney, Australia; Manila, Philippines; Tokyo, Japan; and Seoul, South Korea, as well as other ad hoc charters. As of December 31, 2010, its fleet consisted of 15 Boeing 717-200 aircraft for its interisland routes; 18 Boeing 767-300; and 3 Airbus A330-200 aircrafts for its transpacific, Pacific, and charter routes. Hawaiian Holdings, Inc. was founded in 1929 and is headquartered in Honolulu, Hawaii.
Advisors' Opinion:- [By Ben Levisohn]
DeNardi also rates Alaska Air (ALK), Spirit Airlines (SAVE) and Allegiant Travel (ALGT) as Buys and Southwest, JetBlue Airways (JBLU) and Hawaiian Holdings (HA) as holds.
- [By Adam Levine-Weinberg]
While most of the U.S. airline industry has been sailing along for the past two years, Hawaiian Holdings, (NASDAQ: HA ) has hit some rough patches. Unit revenue declined in 2013 due to a combination of overcapacity on some routes, and unfavorable currency fluctuations.
No comments:
Post a Comment